Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies

Abstract

Antibody-drug conjugates (ADCs) have emerged as a transformative class in oncology, integrating the target specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule payloads. By harnessing tumor-specific antigen recognition, ADCs enable the selective delivery of chemotherapeutic agents, thereby enhancing therapeutic efficacy while reducing systemic toxicity. Their clinical success across both hematologic malignancies and solid tumors underscores their potential to redefine targeted cancer therapy. However, the clinical durability of ADCs is increasingly undermined by the emergence of diverse resistance mechanisms that diminish their antitumor activity. These mechanisms encompass the entire drug delivery cascade - from reduced or heterogeneous antigen expression and impaired internalization to defective lysosomal trafficking, enhanced drug efflux, and payload detoxification. In addition, adaptive reprogramming of oncogenic signaling pathways and tumor microenvironmental factors can further attenuate ADC cytotoxicity and promote tumor persistence. A comprehensive understanding of the molecular and cellular bases of ADC resistance is essential for sustaining their therapeutic impact. Advances in linker chemistry, innovative payload design, and the development of bispecific or immune-modulating ADCs offer promising strategies to overcome these challenges. Concurrently, the integration of biomarker-driven patient selection and rational combination regimens is poised to enhance treatment precision and delay resistance. Continued mechanistic and translational research will be pivotal to fully realizing the potential of next-generation ADCs in precision oncology.

Keywords

Antibody-drug conjugates / resistance / mechanism / challenges / future directions

References

[1] Abuhelwa Z,Nagasaka M.A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).Cancer Treat Rev2022;106:102393 PMCID:PMC12582167

[2] Ippolito MR,Martin S.Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy.Dev Cell2021;56:2440-54.e6

[3] Liu K,Li Y.A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers.Mol Cancer2024;23:62 PMCID:PMC10960395

[4] Jiang M,Xu B.Spotlight on ideal target antigens and resistance in antibody-drug conjugates: strategies for competitive advancement.Drug Resist Updat2024;75:101086

[5] Bardia A, Jhaveri K, Im SA, et al.; TROPION-Breast01 Investigators. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01.J Clin Oncol2025;43:285-96 PMCID:PMC11771365

[6] Fu Z,Han S,Zhang Y.Antibody drug conjugate: the “biological missile” for targeted cancer therapy.Signal Transduct Target Ther2022;7:93 PMCID:PMC8941077

[7] Coats S,Kebble B.Antibody-drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index.Clin Cancer Res2019;25:5441-8

[8] Drago JZ,Chandarlapaty S.Unlocking the potential of antibody-drug conjugates for cancer therapy.Nat Rev Clin Oncol2021;18:327-44 PMCID:PMC8287784

[9] Dong Y,Luan S.Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses.J Immunother Cancer2024;12:e009710 PMCID:PMC11448212

[10] Khoury R,Khalife N.Mechanisms of resistance to antibody-drug conjugates.Int J Mol Sci2023;24:9674 PMCID:PMC10253543

[11] Xu Z,Jiang Z.Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan(DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985).Eur J Med Chem2019;183:111682

[12] Firestone RS,Shekarkhand T.Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.Blood2024;144:402-7 PMCID:PMC11302451

[13] Aslan M,Garcia-Marques FJ.Oncogene-mediated metabolic gene signature predicts breast cancer outcome.NPJ Breast Cancer2021;7:141 PMCID:PMC8553750

[14] D’Amico L,Prummer M.A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.J Immunother Cancer2019;7:16 PMCID:PMC6341578

[15] Meric-Bernstam F,Evans KW.Antitumor activity and biomarker analysis for TROP2 antibody-drug conjugate datopotamab deruxtecan in patient-derived breast cancer xenograft models.Clin Cancer Res2025;31:573-87 PMCID:PMC11788653

[16] Li S,Fu K.Resistance to antibody-drug conjugates: a review.Acta Pharm Sin B2025;15:737-56 PMCID:PMC11959940

[17] Aggen DH,Rosenberg JE.Scratching the surface: NECTIN-4 as a surrogate for enfortumab vedotin resistance.Clin Cancer Res2023;29:1377-80 PMCID:PMC10106381

[18] Klümper N,Ellinger J.Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance.Clin Cancer Res2023;29:1496-505 PMCID:PMC10102834

[19] Saleh K,Khalife N.Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer.Cancer Drug Resist2024;7:22 PMCID:PMC11267152

[20] Tsao LC,Ma X.Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd).Nat Commun2025;16:3167 PMCID:PMC11965298

[21] Filho OM,Stein S.Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab.Cancer Discov2021;11:2474-87 PMCID:PMC8598376

[22] Sperinde J,Vehtari A.p95HER2 methionine 611 carboxy-terminal fragment is predictive of trastuzumab adjuvant treatment benefit in the FinHer trial.Clin Cancer Res2018;24:3046-52

[23] Singh AP,Verma A,Thurber GM.Antibody coadministration as a strategy to overcome binding-site barrier for ADCs: a quantitative investigation.AAPS J2020;22:28 PMCID:PMC8382310

[24] Krop IE,Barrios C.Trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab after anthracycline for high-risk human epidermal growth factor receptor 2-positive early breast cancer: the phase III KAITLIN study.J Clin Oncol2022;40:438-48 PMCID:PMC8824393

[25] Zhang M,Liao H.Targeting HER3 or MEK overcomes acquired trastuzumab resistance in HER2-positive gastric cancer-derived xenograft.Cell Death Discov2022;8:478 PMCID:PMC9719506

[26] Foss S,Aguinagalde L.Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria.Nat Commun2024;15:2007 PMCID:PMC10920689

[27] Peters S,André F.Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.Ann Oncol2024;35:607-29

[28] Li BT,Misale S.HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers.Cancer Discov2020;10:674-87 PMCID:PMC7196485

[29] Duro-Sánchez S,Lalinde-Gutiérrez M.Therapy-induced senescence enhances the efficacy of HER2-targeted antibody-drug conjugates in breast cancer.Cancer Res2022;82:4670-9 PMCID:PMC9755966

[30] Chen R,Hou J.Inhibition of MDR1 overcomes resistance to brentuximab vedotin in hodgkin lymphoma.Clin Cancer Res2020;26:1034-44 PMCID:PMC7056527

[31] Chen R,Newman E.CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin.Mol Cancer Ther2015;14:1376-84 PMCID:PMC4458438

[32] Cabaud O,Crompot E.Overcoming resistance to anti-nectin-4 antibody-drug conjugate.Mol Cancer Ther2022;21:1227-35

[33] Rosenberg J,Zhang J.EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma.J Clin Oncol2020;38:1041-9 PMCID:PMC7106979

[34] Bardia A,Thimmiah N.Antibody-drug conjugate sacituzumab govitecan enables a sequential TOP1/PARP inhibitor therapy strategy in patients with breast cancer.Clin Cancer Res2024;30:2917-24 PMCID:PMC11247314

[35] Coates JT,Leshchiner I.Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer.Cancer Discov2021;11:2436-45 PMCID:PMC8495771

[36] Chen YF,Shao ZM.Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions.Cancer Commun2023;43:297-337 PMCID:PMC10009672

[37] Qiu D,Chennamsetty N,Hay M.Characterizing and understanding the formation of cysteine conjugates and other by-products in a random, lysine-linked antibody drug conjugate.MAbs2021;13:1974150 PMCID:PMC8425761

[38] López de Sá A,Poyatos-Racionero E.Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.J Hematol Oncol2023;16:118 PMCID:PMC10717055

[39] Zhang J,Li Q.The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer.Cell Death Differ2020;27:2710-25 PMCID:PMC7429833

[40] Tomabechi R,Sato T.SLC46A3 is a lysosomal proton-coupled steroid conjugate and bile acid transporter involved in transport of active catabolites of T-DM1.PNAS Nexus2022;1:pgac063 PMCID:PMC9896951

[41] Li G,Shen BQ.Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells.Mol Cancer Ther2018;17:1441-53

[42] Marin BM,Jain S.Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.Neuro Oncol2021;23:2042-53 PMCID:PMC8643472

[43] Kabraji S,Sammons S.Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases.Clin Cancer Res2023;29:174-82 PMCID:PMC9811155

[44] Krop IE, Kim SB, González-Martín A, et al.; TH3RESA study collaborators. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.Lancet Oncol2014;15:689-99

[45] He J,Wang C,Li Y.Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies.MedComm2024;5:e671 PMCID:PMC11283588

[46] Ríos-Luci C,Díaz-Rodríguez E.Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity.Cancer Res2017;77:4639-51

[47] Yokoyama D,Deguchi Y.PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma.Sci Rep2021;11:9013 PMCID:PMC8079403

[48] Liu X,Li J.Trop2-targeted therapies in solid tumors: advances and future directions.Theranostics2024;14:3674-92 PMCID:PMC11209721

[49] Irie H,Fujioka Y.Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728.Cancer Sci2020;111:2123-31 PMCID:PMC7293079

[50] Lipert BA,Khan A.CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance.Breast Cancer Res2025;27:48 PMCID:PMC11959757

[51] Saxton RA.mTOR signaling in growth, metabolism, and disease.Cell2017;168:960-76

[52] Islam SS,Noman ASM.Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1.EBioMedicine2019;43:211-24 PMCID:PMC6558306

[53] Wang L,Xu P.YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer.Br J Cancer2020;123:1000-11 PMCID:PMC7494777

[54] Lee J,Koh J.The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.J Exp Clin Cancer Res2024;43:236 PMCID:PMC11337831

[55] Mosele F,Lusque A.Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.Nat Med2023;29:2110-20 PMCID:PMC10427426

[56] Saatci Ö,Akbulut Ö.Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.Oncogene2018;37:2251-69

[57] Sabbaghi M,Guardia C.Defective Cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer.Clin Cancer Res2017;23:7006-19

[58] Bourbon E.Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.Expert Opin Investig Drugs2020;29:1079-88

[59] García-Alonso S,Pandiella A.Resistance to antibody-drug conjugates.Cancer Res2018;78:2159-65

[60] Tsuchikama K,Ha SYY.Exploring the next generation of antibody-drug conjugates.Nat Rev Clin Oncol2024;21:203-23

[61] Weng W,Zhao Q.Antibody-exatecan conjugates with a novel self-immolative moiety overcome resistance in colon and lung cancer.Cancer Discov2023;13:950-73

[62] Notabi MK,Andersen MØ.Antibody conjugated lipid nanoparticles as a targeted drug delivery system for hydrophobic pharmaceuticals.Eur J Pharm Sci2021;161:105777

[63] Marques AC,Velho S.Lipid nanoparticles functionalized with antibodies for anticancer drug therapy.Pharmaceutics2023;15:216 PMCID:PMC9864942

[64] Zhu J,Lu J.Metabolism-guided development of Ko143 analogs as ABCG2 inhibitors.Eur J Med Chem2023;259:115666 PMCID:PMC10529637

[65] Wei Q,Yang T.The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors.J Hematol Oncol2024;17:1 PMCID:PMC10768262

[66] Journeaux T.Homogeneous multi-payload antibody-drug conjugates.Nat Chem2024;16:854-70

[67] Conilh L,Viricel W.Payload diversification: a key step in the development of antibody-drug conjugates.J Hematol Oncol2023;16:3 PMCID:PMC9847035

[68] Rugo HS,Marmé F.Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.J Clin Oncol2022;40:3365-76

[69] Zhong H,Tammali R.Improved therapeutic window in BRCA-mutant tumors with antibody-linked pyrrolobenzodiazepine dimers with and without PARP inhibition.Mol Cancer Ther2019;18:89-99

[70] Nervig CS,Marelli M,Owen SC.Modular synthesis of anti-HER2 dual-drug antibody-drug conjugates demonstrating improved toxicity.Bioconjug Chem2025;36:190-202

[71] Min Y,Wang L.Supramolecular antibody-drug conjugates for combined antibody therapy and photothermal therapy targeting HER2-positive cancers.Int J Biol Macromol2024;278:134622

[72] Loganzo F,Gerber HP.Mechanisms of resistance to antibody-drug conjugates.Mol Cancer Ther2016;15:2825-34

[73] Kang JC,Khare P.Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy.Nat Biotechnol2019;37:523-6 PMCID:PMC6668989

[74] Shefet-Carasso L.Antibody-targeted drugs and drug resistance - challenges and solutions.Drug Resist Updat2015;18:36-46

[75] Zhou L,Liu W.Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.Exp Hematol Oncol2024;13:26 PMCID:PMC10908151

[76] Kesireddy M,Gundepalli SG.A review of the current FDA-approved antibody-drug conjugates: landmark clinical trials and indications.Pharmaceut Med2024;38:39-54

[77] Emens LA,Beresford M.Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.Lancet Oncol2020;21:1283-95

[78] Gennari A, André F, Barrios CH, et al.; ESMO Guidelines Committee. Electronic address: [e-mail]. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.Ann Oncol2021;32:1475-95

[79] Rios-Doria J,Rothstein R.Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies.Cancer Res2017;77:2686-98

[80] von Arx C,Caltavituro A.The evolving therapeutic landscape of trastuzumab-drug conjugates: future perspectives beyond HER2-positive breast cancer.Cancer Treat Rev2023;113:102500

[81] Wang Z,Gou L,Wang Y.Antibody-drug conjugates: recent advances in payloads.Acta Pharm Sin B2023;13:4025-59 PMCID:PMC10547921

[82] Fabre M,Domínguez-Hormaetxe S.OMTX705, a novel FAP-targeting ADC demonstrates activity in chemotherapy and pembrolizumab-resistant solid tumor models.Clin Cancer Res2020;26:3420-30

[83] Zhou M,Ma Z.The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy.Cancer Drug Resist2025;8:34 PMCID:PMC12366496

[84] Brandl F,Zangemeister-Wittke U.Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life.J Control Release2020;327:186-97

[85] Murase Y,Ueda T.Mechanisms of resistance to antibody-drug conjugates in cancers.Respir Investig2025;63:693-8

[86] Engebraaten O,Berg K.RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.Nat Commun2021;12:6427 PMCID:PMC8571323

[87] Bosi C,Galbardi B.Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.Eur J Cancer2023;195:113379

[88] Dean TT,Allen AC.Peptide-drug conjugates: an emerging direction for the next generation of peptide therapeutics.J Med Chem2024;67:1641-61 PMCID:PMC10922862

[89] Ambrosini V.Radioguided surgery with 68Ga-DOTATATE for patients with neuroendocrine tumors.Hepatobiliary Surg Nutr2020;9:67-9 PMCID:PMC7026788

[90] Kumthekar P,Brenner AJ.ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases.Clin Cancer Res2020;26:2789-99

[91] Wang D,Li Z,Shi C.Current progress and remaining challenges of peptide-drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?.J Nanobiotechnology2025;23:305 PMCID:PMC12013038

[92] Li C,Wang Y.Self-assembly of CXCR4 antagonist peptide-docetaxel conjugates for breast tumor multi-organ metastasis inhibition.Acta Pharm Sin B2023;13:3849-61 PMCID:PMC10501865

[93] Kong FE,Tang YQ.Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate.Sci Transl Med2021;13:eabb6282

[94] Wang L,He Q.A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment.Theranostics2025;15:1238-54 PMCID:PMC11729552